Welcome to the Hope Bio Blog

Hope Bio’s CTTACC 2023 Recap What do you get when you send two scientists and two executives to the desert? While you search for a punchline, we’ll supply our experientially discovered answer - you get great and growing industry relationships, breaking news in cell therapy and traumatic brain injury, and a whole lot o’ pictures of a cell culture flask in exotic (by cell culture flask standards) locations. CTTACC 2023 main session A huge “thank you” to Scottsdale, Arizona for

A four-year, nearly $5 million clinical trial grant awarded to UTHealth Houston by the Department of Defense’s Office of Congressionally Directed Medical Research Programs (CDMRP) will evaluate if intravenously infused Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce chronic neuroinflammatory response to severe traumatic brain injury (TBI). UTHealth Houston and Hope Bio celebrating completion of treatments in the Phase I trial for Trauma

– FOR IMMEDIATE RELEASE – Sugar Land, Texas, 5 April 2022: Houston area biotechnology and stem cell banking company Hope Biosciences marks its six-year anniversary this month, celebrating nearly 200 billion cultured mesenchymal stem cells and the myriad of ways those cells are benefitting clients. Hope Biosciences occupies a unique position in the regenerative medicine space, noteworthy both for patented cell culture methods and its effectiveness getting cells to patients th